Literature DB >> 22198291

Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.

V N P Le1, E Robins, M P Flament.   

Abstract

Due to their small size, the respirable drug particles tend to form agglomerates which prevent flowing and aerosolisation. A carrier is used to be mixed with drug in one hand to facilitate the powder flow during manufacturing, in other hand to help the fluidisation upon patient inhalation. Depending on drug concentration, drug agglomerates can be formed in the mixture. The aim of this work was to study the agglomeration behaviour of fluticasone propionate (FP) within interactive mixtures for inhalation. The agglomerate phenomenon of fluticasone propionate after mixing with different fractions of lactose without fine particles of lactose (smaller than 32 μm) was demonstrated by the optical microscopy observation. A technique measuring the FP size in the mixture was developed, based on laser diffraction method. The FP agglomerate sizes were found to be in a linear correlation with the pore size of the carrier powder bed (R(2)=0.9382). The latter depends on the particle size distribution of carrier. This founding can explain the role of carrier size in de-agglomeration of drug particles in the mixture. Furthermore, it gives more structural information of interactive mixture for inhalation that can be used in the investigation of aerosolisation mechanism of powder. According to the manufacturing history, different batches of FP show different agglomeration intensities which can be detected by Spraytec, a new laser diffraction method for measuring aerodynamic size. After mixing with a carrier, Lactohale LH200, the most cohesive batch of FP, generates a lower fine particle fraction. It can be explained by the fact that agglomerates of fluticasone propionate with very large size was detected in the mixtures. By using silica-gel beads as ball-milling agent during the mixing process, the FP agglomerate size decreases accordingly to the quantity of mixing aid. The homogeneity and the aerodynamic performance of the mixtures are improved. The mixing aid based on ball-milling effect could be used to ameliorate the quality of inhalation mixture of cohesive drug, such as fluticasone propionate. However, there is a threshold where an optimal amount of mixing aids should be used. Not only the drug des-aggregation reaches its peak but the increase in drug-carrier adhesion due to high energy input should balance the de-agglomeration capacity of mixing process. This approach provides a potential alternative in DPI formulation processing.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198291     DOI: 10.1016/j.ejpb.2011.12.004

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Freeze-dried mannitol for superior pulmonary drug delivery via dry powder inhaler.

Authors:  Waseem Kaialy; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-10-16       Impact factor: 4.200

2.  Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.

Authors:  Hiroko Otake; Tomoyuki Okuda; Daiki Hira; Haruyoshi Kojima; Yasuhiro Shimada; Hirozazu Okamoto
Journal:  Pharm Res       Date:  2015-12-07       Impact factor: 4.200

3.  Dry Powder Inhalers for Proteins Using Cryo-Milled Electrospun Polyvinyl Alcohol Nanofiber Mats.

Authors:  Takaaki Ito; Eriko Yamazoe; Kohei Tahara
Journal:  Molecules       Date:  2022-08-12       Impact factor: 4.927

4.  Mixing time effects on the dispersion performance of adhesive mixtures for inhalation.

Authors:  Floris Grasmeijer; Paul Hagedoorn; Henderik W Frijlink; H Anne de Boer
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

5.  Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.

Authors:  Sara Jaffari; Ben Forbes; Elizabeth Collins; Jiyi Khoo; Gary P Martin; Darragh Murnane
Journal:  Pharm Res       Date:  2014-12       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.